Minneapolis, MN — November 4, 2025 — Leads & Copy — CVRx, Inc. (NASDAQ: CVRX) will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at 8:00 a.m. (GMT) / 4:00 a.m. (ET).
A live audio webcast of the presentation will be available at ir.cvrx.com.
CVRx is a commercial-stage medical device company focused on neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first FDA-approved technology using neuromodulation to improve heart failure symptoms. Barostim is an implantable device delivering electrical pulses to baroreceptors, restoring balance to the autonomic nervous system. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area.
Investor Contact: Mark Klausner or Mike Vallie, ICR Healthcare, 443-213-0501, ir@cvrx.com; Media Contact: Emily Meyers, CVRx, Inc., 763-416-2853, emeyers@cvrx.com
Source: CVRx, Inc.
